The Latest Breaking News from Biogen

"This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline," Eli Lilly said.

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease

Biogen stock was hamstrung Wednesday on mixed 2023 guidance that assumes expenses for its new Alzheimer's drug will outpace sales.

The Dow Jones fell 200 points Wednesday on strong U.S. retail sales data. Tesla stock reversed lower even after a Barclays outperform rating.

The market rally held up despite hot inflation data. Boeing led new buys while Tesla ran higher. Airbnb soared late on earnings.

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimer's treatment.

"We are committed to working with the FDA to ensure the fastest possible path to bring this potential medicine to patients in need," Eli Lilly said.